Tiotropium was superior to placebo in mean change from baseline in post-dose FEV1 area under the curve from 0 to 3h ( AUC0-3h ) at week 24 ( primary endpoint ) : 0.19 vs. -0.03 l ( least-squares mean difference 0.23 l , P < 0.001 ) .